Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
EVFM Evofem Biosciences
0.170
-0.012-6.74%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
224.93% 6.03M 284.71% 4.25M 1748.43% 8.24M 2025% 3.57M
Operating revenue
224.93% 6.03M 284.71% 4.25M 1748.43% 8.24M 2025% 3.57M
Cost of revenue
53.16% 1.29M 110.67% 1.07M 766.45% 4.06M 1062.25% 1.76M
Gross profit
366.5% 4.75M 431.72% 3.19M 19140.91% 4.19M 10576.47% 1.82M
Operating expense
-30.82% 29.17M -29.37% 32.11M 65.05% 170.99M 9.38% 39.23M
Selling and administrative expenses
-36.34% 21.42M -43.15% 21.72M 59.28% 137.86M 2.18% 30.57M
-Selling and marketing expense
-54.85% 12.3M -58.38% 12.71M 100.39% 113.15M 4.22% 24.92M
-General and administrative expense
42.24% 9.13M 17.36% 9.02M -17.87% 24.71M -5.93% 5.65M
Research and development costs
-8.97% 7.74M 43.09% 10.39M 94.3% 33.13M 45.63% 8.66M
Operating profit
40.65% -24.42M 35.53% -28.93M -60.97% -166.8M -4.37% -37.42M
Net non-operating interest income expense
0% 4K -85.71% 1K -91.12% 15K -94.12% 1K
Non-operating interest income
0% 4K -85.71% 1K -91.12% 15K -94.12% 1K
Other net income (expense)
-1414.67% -101.55M -129.76% -2.96M 1.19% -38.39M -196.75% -14.13M
Gain on sale of security
-1235.02% -101.13M -1650.7% -2.49M 8.46% -33.66M -250.14% -12.92M
Other non- operating income (expenses)
65.01% -415K 58.86% -471K -127.28% -4.73M -12.97% -1.21M
Income before tax
-276.97% -125.96M 30.91% -31.89M -44.18% -205.18M -26.98% -51.55M
Income tax
66.67% 20K 400% 3K 325% 17K 200% 6K
Net income
-276.89% -125.98M 30.91% -31.89M -44.19% -205.19M -26.99% -51.55M
Net income continuous Operations
-276.89% -125.98M 30.91% -31.89M -44.19% -205.19M -26.99% -51.55M
Minority interest income
Net income attributable to the parent company
-276.89% -125.98M 30.91% -31.89M -44.19% -205.19M -26.99% -51.55M
Preferred stock dividends
-1.91M 81K 1.05M 1.05M
Other preferred stock dividends
Net income attributable to common stockholders
-271.18% -124.07M 30.73% -31.97M -44.92% -206.24M -29.57% -52.6M
Basic earnings per share
-12.84% -4.57 65.7% -2.8814 25.47% -23.6999 34% -4.95
Diluted earnings per share
-12.84% -4.57 65.7% -2.8814 25.47% -23.6999 34% -4.95
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
CEO: Pelletier, Saundra
Market: Pink Market
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top